

REFERENCES:

1. Delsol G, Lamant L, Mariamé B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. *Blood*. 1997;89:1483–1490.
2. Swerdlow SH, Campo E, Harris NL, et al (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017.
3. Pan Z, Hu S, Li M, et al. ALK-positive Large B-cell Lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature. *Am J Surg Pathol*. 2017;41:21-35.
4. Gong Q, Huntsman C, Ma D. Clathrin-independent internalization and recycling. *J Cell Mol Med*. 2008;12:126–144.
5. De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. *Blood*. 2003;102:2638–2641.
6. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. *J Clin Oncol*. 2009;27:4211–4216.